Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction with bortezomib, lenalidomide and dexamethasone (VRd) to treat adults with ...

Regeneron has announced that the European Commission ... Gynaecological Oncological Trial groups (ENGOT), and NRG Oncology-Japan. Patients were of a median age of 51 years old – 78% with ...

Regeneron Pharmaceuticals (NASDAQ:REGN) is one of the leaders in the ophthalmic disease therapeutics market. In this article, dear Seeking Alpha readers, I present five factors that explain why I ...